Buprenorphine Hydrochloride; Naloxone Hydrochloride Patent Expiration
Buprenorphine Hydrochloride; Naloxone Hydrochloride is used for treating opioid dependence and opioid use disorder. It was first introduced by Indivior Inc
Buprenorphine Hydrochloride; Naloxone Hydrochloride Patents
Given below is the list of patents protecting Buprenorphine Hydrochloride; Naloxone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bunavail | US9522188 | Abuse resistant transmucosal drug delivery device | Apr 24, 2035 | Bdsi |
| Zubsolv | US10874661 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Sep 18, 2032 | Orexo Us Inc |
| Zubsolv | US10946010 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Sep 18, 2032 | Orexo Us Inc |
| Zubsolv | US11020387 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Sep 18, 2032 | Orexo Us Inc |
| Zubsolv | US11020388 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Sep 18, 2032 | Orexo Us Inc |
| Zubsolv | US11433066 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Sep 18, 2032 | Orexo Us Inc |
| Zubsolv | US8940330 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Sep 18, 2032 | Orexo Us Inc |
| Zubsolv | US9259421 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Sep 18, 2032 | Orexo Us Inc |
| Zubsolv | US9439900 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Sep 18, 2032 | Orexo Us Inc |
| Bunavail | US8703177 | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | Aug 20, 2032 | Bdsi |
| Zubsolv | US8470361 | Non-abusable pharmaceutical composition comprising opioids | May 22, 2030 | Orexo Us Inc |
| Suboxone | US8475832 | Sublingual and buccal film compositions | Mar 26, 2030 | Indivior |
| Suboxone | US11135216 | Sublingual and buccal film compositions | Aug 07, 2029 | Indivior |
| Suboxone | US9687454 | Sublingual and buccal film compositions | Aug 07, 2029 | Indivior |
| Zubsolv | US8658198 | Non-abusable pharmaceutical composition comprising opioids | Dec 03, 2027 | Orexo Us Inc |
| Bunavail | US8147866 | Transmucosal delivery devices with enhanced uptake | Jul 23, 2027 | Bdsi |
| Bunavail | US9655843 | Transmucosal delivery devices with enhanced uptake | Jul 23, 2027 | Bdsi |
| Suboxone | US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr 03, 2024
(Expired) | Indivior |
| Suboxone | US8017150 | Polyethylene oxide-based films and drug delivery systems made therefrom |
Feb 13, 2023
(Expired) | Indivior |
| Suboxone | US10285910 | Sublingual and buccal film compositions |
Oct 11, 2022
(Expired) | Indivior |
| Suboxone | US9855221 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb 14, 2022
(Expired) | Indivior |
| Suboxone | US9931305 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb 14, 2022
(Expired) | Indivior |
| Bunavail | US7579019 | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
Jan 22, 2020
(Expired) | Bdsi |
| Zubsolv | US8454996 | Pharmaceutical composition for the treatment of acute disorders |
Sep 24, 2019
(Expired) | Orexo Us Inc |
| Bunavail | US6159498 | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces |
Oct 18, 2016
(Expired) | Bdsi |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Buprenorphine Hydrochloride; Naloxone Hydrochloride's patents.
Latest Legal Activities on Buprenorphine Hydrochloride; Naloxone Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Buprenorphine Hydrochloride; Naloxone Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Jun, 2024 | US10874661 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Mar, 2024 | US9439900(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Aug, 2023 | US9259421(Litigated) |
| Expire Patent Critical
| 19 Jun, 2023 | US10285910 |
| Maintenance Fee Reminder Mailed Critical
| 02 Jan, 2023 | US10285910 |
| Review Certificate Mailed | 30 Sep, 2022 | US9687454(Litigated) |
| Review Certificate | 23 Sep, 2022 | US9687454(Litigated) |
| Recordation of Patent Grant Mailed Critical
| 06 Sep, 2022 | US11433066 |
| Patent Issue Date Used in PTA Calculation Critical
| 06 Sep, 2022 | US11433066 |
| Email Notification Critical
| 18 Aug, 2022 | US11433066 |
Buprenorphine Hydrochloride; Naloxone Hydrochloride's Family Patents
